At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNXT RenovoRx Inc
Post-Market Trading 11-22 17:01:12 EST
1.29
+0.08
+6.60%
盘后1.35
+0.06+4.65%
16:39 EST
High1.58
Low1.18
Vol262.81K
Open1.30
D1 Closing1.21
Amplitude32.72%
Mkt Cap30.94M
Tradable Cap30.35M
Total Shares23.99M
T/O359.58K
T/O Rate1.12%
Tradable Shares23.53M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial
RenovoRx Increases Production of FDA-Cleared Renovocath® Delivery System in Response to Strong Demand From Oncology and Interventional Radiology Physicians
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting Tamp™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.